← All trials
NCT03656120
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2018
- Primary completion
- Aug 31, 2019
- Completion date
- Dec 31, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 180
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of MichiganLead sponsor
- Huazhong University of Science and TechnologyCollaborator
- Sichuan UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Central South UniversitySponsor investigator
- Beijing ziduhongye technology development co. LTDCollaborator
- People's Liberation Army of ChinaCollaborator
- Central South UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.